Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
Warning: file_get_contents(http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=19481107&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 445
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Alzheimer s disease and blood-brain barrier function-Why have anti-beta-amyloid therapies failed to prevent dementia progression?Pahnke J; Walker LC; Scheffler K; Krohn MNeurosci Biobehav Rev 2009[Jul]; 33 (7): 1099-108Proteopathies of the brain are defined by abnormal, disease-inducing protein deposition that leads to functional abrogation and death of neurons. Immunization trials targeting the removal of amyloid-beta plaques in Alzheimer's disease have so far failed to stop the progression of dementia, despite autopsy findings of reduced plaque load. Here, we summarize current knowledge of the relationship between AD pathology and blood-brain barrier function, and propose that the activation of the excretion function of the blood-brain barrier might help to achieve better results in trials targeting the dissolution of cerebral amyloid-beta aggregates. We further discuss a possible role of oligomers in limiting the efficacy of immunotherapy.|*Immunotherapy[MESH]|ATP-Binding Cassette Transporters/metabolism[MESH]|Alzheimer Disease/epidemiology/*physiopathology/*therapy[MESH]|Amyloid beta-Peptides/immunology/*metabolism[MESH]|Animals[MESH]|Blood-Brain Barrier/drug effects/*physiopathology[MESH]|Cost of Illness[MESH]|Disease Progression[MESH]|Humans[MESH]|Neurodegenerative Diseases/physiopathology[MESH]|Prevalence[MESH] |
